NAMS 2022 Hormone Therapy Benefits Risks Guidance

Byalsapataca
🟢
Peer-Reviewed Research

Hormone Replacement Therapy: The 2022 NAMS Position on Risks, Benefits, and Individualized Care

The 2022 position statement from The North American Menopause Society (NAMS), representing the consensus of an expert Advisory Panel, states that hormone therapy remains the most effective treatment for menopausal vasomotor symptoms like hot flashes and for the genitourinary syndrome of menopause. This definitive guidance clarifies that the risks of treatment are not uniform but depend on a woman’s age, time since menopause, and the specific type, dose, and delivery method of hormones used.

What Hormone Replacement Therapy Is and Why It Is Used

Hormone replacement therapy (HRT), also called menopausal hormone therapy, involves administering estrogen, often combined with progesterone (or a progestogen), to replace the hormones a woman’s ovaries stop producing during the menopause transition. The primary clinical goal is to relieve the disruptive symptoms caused by this sharp hormonal decline.

Estrogen levels directly influence the body’s temperature regulation, which is why a drop can trigger sudden, intense hot flashes and night sweats. These vasomotor symptoms affect up to 80% of women and can severely impair sleep and quality of life. Estrogen is also essential for maintaining the health and elasticity of vaginal and urinary tract tissues. Its depletion leads to the genitourinary syndrome of menopause, characterized by vaginal dryness, pain during intercourse, and recurrent urinary tract infections.

Beyond symptom relief, estrogen plays a critical role in bone metabolism. Its decline accelerates bone loss, dramatically increasing fracture risk. Systemic HRT has been proven to prevent this loss and reduce fractures. Treatment is not a one-size-fits-all solution but a medical strategy tailored to individual symptoms, health history, and risks.

The Science of Benefit and Risk: Timing, Type, and Duration Matter

Our understanding of HRT’s safety profile shifted significantly after long-term follow-up from the landmark Women’s Health Initiative (WHI) trial. Researchers like Dr. JoAnn E. Manson, a co-author on both cited papers, have emphasized that the initial 2002 findings, which raised alarms about heart disease and breast cancer, primarily applied to an older cohort of women who were many years past menopause. Subsequent analyses painted a more nuanced picture.

The Critical “Window of Opportunity”

The NAMS 2022 statement provides a clear framework based on age and time since menopause. For women under 60 or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio for treating bothersome vasomotor symptoms and preventing bone loss is favorable. For this group, the absolute risks of serious events like coronary heart disease, stroke, venous thromboembolism, and dementia are low.

The calculus changes for women who initiate therapy more than 10 years from menopause onset or who are over 60. In this group, the absolute risks of the conditions noted above are greater, making the benefit-risk ratio less favorable. This underscores a core principle: HRT is not recommended for the primary prevention of chronic diseases like heart disease or dementia in older postmenopausal women.

How Formulation and Delivery Alter Risk

Risk is not determined by the hormone alone but by how it enters the body. Oral estrogen passes through the liver, which can increase the production of clotting factors, thereby raising the risk of venous thromboembolism and stroke. Transdermal methods—patches, gels, or sprays—deliver estrogen directly into the bloodstream, bypassing this “first-pass” liver effect. Evidence suggests transdermal estrogen carries a lower risk of blood clots and stroke compared to oral forms.

The need for a progestogen is another key variable. Women with a uterus must take a progestogen alongside estrogen to prevent estrogen-induced overgrowth of the uterine lining (endometrial hyperplasia), which can lead to cancer. This addition can influence breast cancer risk profiles. Women who have had a hysterectomy can use estrogen-alone therapy, which in the WHI trial showed a more favorable safety profile regarding breast cancer risk.

Practical Applications: Personalizing Treatment Decisions

Applying the evidence requires a personalized strategy built on shared decision-making between a woman and her clinician. The goal is to use the lowest effective dose for the shortest duration needed to manage quality-of-life goals while periodically reassessing the ongoing need for treatment.

Addressing Vasomotor Symptoms and Bone Health

For moderate to severe hot flashes and night sweats that disrupt daily life, systemic HRT (estrogen with or without a progestogen) is the most effective treatment available. It can reduce the frequency and severity of these symptoms by 75% or more. For women who are candidates based on the “window of opportunity” principle, this high level of efficacy often justifies treatment. The therapy also reliably prevents postmenopausal bone loss, offering an additional benefit for women at increased risk for osteoporosis. For a detailed review of hormonal and non-hormonal options for vasomotor symptoms, see our Evidence-Based Guide to Menopause Supplements reviews the data on various botanical options.

Key Takeaways

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *